Hims & Hers and Novo Nordisk End GLP-1 Dispute Amid Rumors of Collaboration

Hims & Hers faces legal scrutiny over Semaglutide claims and resolves a major dispute with Novo Nordisk regarding Wegovy sales. The end of the feud signals a strategic shift, likely influencing the market dynamics of GLP-1 drugs. Watch for upcoming collaborations or regulatory developments affecting these companies and diabetes treatments.